Analyst Reco. Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
14.95 ^USD	+5.58%		+10.82%	+66.30%

Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI

Analyst Reco.

Mar. 03	Chardan Raises Price Target on Intellia Therapeutics to $27 From $26, Keeps Buy Rating	MT
Mar. 03	RBC Raises Price Target on Intellia Therapeutics to $15 From $9, Keeps Sector Perform, Speculative Risk	MT
Mar. 02	William Blair Upgrades Intellia Therapeutics to Outperform From Market Perform	MT
Mar. 02	Global markets live: Amazon, AWS, Lufthansa, Saudi Aramco, Standard Chartered…
Feb. 27	Wedbush Raises Price Target on Intellia Therapeutics to $12 From $7, Keeps Neutral Rating	MT
Jan. 06	BofA Adjusts Price Target on Intellia Therapeutics to $12 From $14, Maintains Neutral Rating	MT
Nov. 11	Jones Downgrades Intellia Therapeutics to Neutral From Buy	MT
Nov. 11	Evercore ISI Downgrades Intellia Therapeutics to In Line From Outperform, Adjusts PT to $8 From $17	MT
Nov. 10	Intellia Therapeutics, Inc. Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin Amyloidosis with Cardiomyopathy	CI
Nov. 10	Truist Cuts Price Target on Intellia Therapeutics to $14 From $25, Keeps Buy Rating	MT
Nov. 07	RBC Adjusts Price Target on Intellia Therapeutics to $9 From $14, Maintains Sector Perform Rating	MT
Nov. 07	JPMorgan Downgrades Intellia Therapeutics to Underweight From Neutral, Adjusts Price Target to $5 From $12	MT
25-10-31	Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says	MT
25-10-28	Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says	MT
25-10-28	Chardan Cuts Price Target on Intellia Therapeutics to $48 From $60, Keeps Buy Rating	MT
25-10-28	William Blair Downgrades Intellia Therapeutics to Market Perform From Outperrorm	MT
25-10-28	Wells Fargo Downgrades Intellia Therapeutics to Equal Weight From Overweight, Adjusts Price Target to $17 From $45	MT
25-10-28	RBC Downgrades Intellia Therapeutics to Sector Perform From Outperform, Cuts Price Target to $14 From $21, Keeps Speculative Risk	MT
25-10-27	Intellia Therapeutics Shares Fall After Pausing Patient Dosing, Screening in Phase 3 Nex-Z Trials	MT
25-10-27	Intellia Therapeutics provides update on Magnitude clinical trials of Nexiguran Ziclumeran	RE
25-10-27	Intellia pauses gene therapy trials after patient suffers liver injury, shares slide	RE
25-09-26	Wedbush Doubles Price Target on Intellia Therapeutics to $14 From $7, Keeps Neutral Rating	MT
25-08-07	RBC Cuts Price Target on Intellia Therapeutics to $21 From $25, Keeps Outperform Rating	MT
25-07-07	RBC Cuts Price Target on Intellia Therapeutics to $25 From $30, Keeps Outperform, Speculative Risk	MT
25-05-29	Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating	MT